Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

NCT01885208 · Completed

Last updated 2026-05-28

This clinical trial compared the effects of semaglutide once a week versus exenatide once a week, both added to existing diabetes medications, in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 813 people

Who can join Ages 18+ · all sexes

Timeline Started 2013-12 · est. completion 2015-07

Where 146 sites · Argentina, Croatia, Finland, France, Germany, Greece, Italy, Netherlands, Puerto Rico, Serbia, Switzerland, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT01885208 ↗

Description as written by the study sponsor.

This trial is conducted in Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of semaglutide once-weekly versus exenatide ER (extended release) 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes.

Treatments tested

semaglutide Drug

One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
exenatide also known as Bydureon® Drug

One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly

Main thing measured	Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide, exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01885208 ↗